Miniatura

Fitxers

662999.pdf (3.38 MB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2016-12-01

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/132979

Therapeutic benefit of selective inhibition of p110α PI3-kinase in pancreatic neuroendocrine tumors

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1158/1078-0432.CCR-15-3051

Resum

Purpose: mutations in the PI3K pathway occur in 16% of patients with pancreatic neuroendocrine tumors (PanNETs), which suggests that these tumors are an exciting setting for PI3K/AKT/mTOR pharmacologic intervention. Everolimus, an mTOR inhibitor, is being used to treat patients with advanced PanNETs. However, resistance tomTOR-targeted therapy is emerging partially due to the loss of mTOR-dependent feedback inhibition of AKT. In contrast, the response to PI3K inhibitors in PanNETs is unknown. Experimental Design: in the current study, we assessed the frequency of PI3K pathway activation in human PanNETs and in RIP1-Tag2 mice, a preclinical tumor model of PanNETs, and we investigated the therapeutic efficacy of inhibiting PI3K in RIP1-Tag2 mice using a combination of pan (GDC-0941) and p110 alpha-selective (GDC-0326) inhibitors and isoform-specific PI3K kinase-dead-mutant mice. Results: human and mouse PanNETs showed enhanced pAKT, pPRAS40, and pS6 positivity compared with normal tissue. Although treatment of RIP1-Tag2 mice with GDC-0941 led to reduced tumor growth with no impact on tumor vessels, the selective inactivation of the p110 alpha PI3K isoform, either genetically or pharmacologically, reduced tumor growth as well as vascular area. Furthermore, GDC-0326 reduced the incidence of liver and lymph node metastasis compared with vehicle-treated mice. We also demonstrated that tumor and stromal cells are implicated in the antitumor activity of GDC-0326 in RIP1-Tag2 tumors. Conclusions: our data provide a rationale for p110a-selective intervention in PanNETs and unravel a new function of this kinase in cancer biology through its role in promoting metastasis.

Matèries

Pàncrees, Inhibidors de fosfodiesterases, Farmacologia

Matèries (anglès)

Pancreas, Phosphodiesterase Inhibitors, Pharmacology

Citació

Col·leccions

Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

SOLER, Adriana, FIGUEIREDO, Ana raquel martins, CASTEL MORALES, Pau, MARTÍN FERNÁNDEZ, Laura, MONELLI, Erika, ANGULO URARTE, Ana, MILÀ GUASCH, Maria, VIÑALS CANALS, Francesc, BASELGA TORRES, Josep, CASANOVAS I CASANOVAS, Oriol, GRAUPERA I GARCIA-MILÀ, Mariona. Therapeutic benefit of selective inhibition of p110α PI3-kinase in pancreatic neuroendocrine tumors. _Clinical Cancer Research_. 2016. Vol. 22, núm. 23, pàgs. 5805-5817. [consulta: 16 de gener de 2026]. ISSN: 1078-0432. [Disponible a: https://hdl.handle.net/2445/132979]

Exportar metadades

JSON - METS

Compartir registre